Zenocutuzumab exhibited efficacy among patients with NRG1 fusion-positive cancers, according to phase 2 data published in The New England Journal of Medicine.Nearly one-third of the cohort — which included patients with multiple tumor types — responded to therapy. Those with non-small cell lung cancer and pancreatic cancer derived the most benefit.
The FDA has granted 510(k) clearance for the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an assay designed to assist pathologists in diagnosing…
Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.
The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.
Arce-Gallego et al. integrate next-generation sequencing with a RAD51 immunofluorescence assay to assess HRR function in advanced prostate cancer. They link RAD51-IF scores to mutations in…
Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.
The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.
More than 2 million new cases of cancer will be diagnosed in the US this year, and more than 600,000 people will die of cancer,…
Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.
The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for women with type 1 diabetes, according to…
Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.
